{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:17:38Z","timestamp":1783163858963,"version":"3.54.6"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008385","name":"Cystic Fibrosis Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.118968","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:17:12Z","timestamp":1779380232000},"page":"118968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A critical analysis on ENaC inhibitors, unravelling molecular medicinal insights and promising research roadmap in the treatment of cystic fibrosis"],"prefix":"10.1016","volume":"315","author":[{"given":"Fabiana","family":"Lo Mascolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Lipani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Giuffrida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilia","family":"Barreca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Bivacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Span\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Valeria","family":"Raimondi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Montalbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Borrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Venturini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Guidone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis J.V.","family":"Galietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Barraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118968_bib1","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.118968_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jcf.2010.12.005","article-title":"An overview of international literature from cystic fibrosis registries. Part 3. Disease incidence, genotype\/phenotype correlation, microbiology, pregnancy, clinical complications, lung transplantation, and miscellanea","volume":"10","author":"Salvatore","year":"2011","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"10.1016\/j.ejmech.2026.118968_bib3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.molmed.2007.05.001","article-title":"Cystic fibrosis: a disease of vulnerability to airway surface dehydration","volume":"13","author":"Boucher","year":"2007","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejmech.2026.118968_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay9669","article-title":"Discovery of a picomolar potency pharmacological corrector of the mutant CFTR chloride channel","volume":"6","author":"Pedemonte","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2026.118968_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-023-34440-0","article-title":"Novel tricyclic pyrrolo-quinolines as pharmacological correctors of the mutant CFTR chloride channel","volume":"13","author":"Renda","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.118968_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116691","article-title":"Identification of 6,9-dihydro-5H-pyrrolo[3,2-h]quinazolines as a new class of F508del-CFTR correctors for the treatment of cystic fibrosis","volume":"276","author":"Barreca","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118968_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118325","article-title":"Modulators of anion channels and transporters as alternative therapeutic agents to normalize airway surface liquid in cystic fibrosis","volume":"302","author":"Lipani","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118968_bib8","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445\u2013Tezacaftor\u2013Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118968_bib9","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118968_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(24)00411-9","article-title":"Vanzacaftor\u2013tezacaftor\u2013deutivacaftor versus elexacaftor\u2013tezacaftor\u2013ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials","volume":"13","author":"Keating","year":"2025","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejmech.2026.118968_bib11","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.coph.2017.10.002","article-title":"Bypassing CFTR dysfunction in cystic fibrosis with alternative pathways for anion transport","volume":"34","author":"Li","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118968_bib12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/367463a0","article-title":"Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits","volume":"367","author":"Canessa","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.118968_bib13","doi-asserted-by":"crossref","DOI":"10.1085\/jgp.202213124","article-title":"Expression of ENaC subunits in epithelia","volume":"154","author":"Frindt","year":"2022","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.ejmech.2026.118968_bib14","doi-asserted-by":"crossref","first-page":"C1682","DOI":"10.1152\/ajpcell.1994.267.6.C1682","article-title":"Membrane topology of the epithelial sodium channel in intact cells","volume":"267","author":"Canessa","year":"1994","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejmech.2026.118968_bib15","doi-asserted-by":"crossref","first-page":"12981","DOI":"10.1016\/S0021-9258(18)99972-2","article-title":"Biochemical analysis of the membrane topology of the amiloride-sensitive Na+ channel","volume":"269","author":"Renard","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.118968_bib16","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1152\/physrev.00007.2002","article-title":"Epithelial sodium channel\/degenerin family of ion channels: a variety of functions for a shared structure","volume":"82","author":"Kellenberger","year":"2002","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2026.118968_bib17","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1152\/physrev.1997.77.2.359","article-title":"Epithelial sodium channels: function, structure, and regulation","volume":"77","author":"Garty","year":"1997","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2026.118968_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.gene.2015.12.061","article-title":"Epithelial sodium channel (ENaC) family: phylogeny, structure-function, tissue distribution, and associated inherited diseases","volume":"579","author":"Hanukoglu","year":"2016","journal-title":"Gene"},{"key":"10.1016\/j.ejmech.2026.118968_bib19","doi-asserted-by":"crossref","first-page":"F684","DOI":"10.1152\/ajprenal.00259.2011","article-title":"ENaC structure and function in the wake of a resolved structure of a family member","volume":"301","author":"Kashlan","year":"2011","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejmech.2026.118968_bib20","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.39340","article-title":"Structure of the human epithelial sodium channel by cryo-electron microscopy","volume":"7","author":"Noreng","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2026.118968_bib21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nm1028","article-title":"Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice","volume":"10","author":"Mall","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.118968_bib22","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1056\/NEJM199907153410304","article-title":"Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism","volume":"341","author":"Kerem","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118968_bib23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1358\/dof.2021.46.6.3275931","article-title":"Inhaled epithelial sodium channel inhibitors as potential agents in cystic fibrosis management","volume":"46","author":"Antoniu","year":"2021","journal-title":"Drugs Future"},{"key":"10.1016\/j.ejmech.2026.118968_bib24","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00946-2020","article-title":"ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies","volume":"56","author":"Mall","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2026.118968_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117040","article-title":"Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis","volume":"282","author":"Danahay","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118968_bib26","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1183\/09031936.93.06091243","article-title":"No added benefit from nebulized amiloride in patients with cystic fibrosis","volume":"6","author":"Graham","year":"1993","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2026.118968_bib27","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/thx.48.8.812","article-title":"Effect of amiloride and saline on nasal mucociliary clearance and potential difference in cystic fibrosis and normal subjects","volume":"48","author":"Middleton","year":"1993","journal-title":"Thorax"},{"key":"10.1016\/j.ejmech.2026.118968_bib28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1136\/adc.73.5.427","article-title":"Nebulised amiloride in respiratory exacerbations of cystic fibrosis: a randomised controlled trial","volume":"73","author":"Bowler","year":"1995","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ejmech.2026.118968_bib29","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM199004263221704","article-title":"A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis","volume":"322","author":"Knowles","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.118968_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/1099-0496(200007)30:1<25::AID-PPUL5>3.0.CO;2-C","article-title":"French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. The Amiloride-AFLM Collaborative Study Group","volume":"30","author":"Pons","year":"2000","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.ejmech.2026.118968_bib31","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1021\/jm051134w","article-title":"Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis","volume":"49","author":"Hirsh","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118968_bib32","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000154776","article-title":"Ffects of benzamil in human cystic fibrosis airway epithelium","author":"Blank","year":"1995","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejmech.2026.118968_bib33","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1113\/expphysiol.1991.sp003555","article-title":"Effect of benzamil on sheep tracheal epithelium","volume":"76","author":"Acevedo","year":"1991","journal-title":"Exp. Physiol."},{"key":"10.1016\/j.ejmech.2026.118968_bib34","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1124\/jpet.104.071886","article-title":"Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease","volume":"311","author":"Hirsh","year":"2004","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2026.118968_bib35","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1164\/ajrccm.157.6.9709043","article-title":"Effects of topically delivered benzamil and amiloride on nasal potential difference in cystic fibrosis","volume":"157","author":"Hofmann","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2026.118968_bib36","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1034\/j.1399-3003.1999.14c32.x","article-title":"The effect of topical benzamil and amiloride on nasal potential difference in cystic fibrosis","volume":"14","author":"Rodgers","year":"1999","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2026.118968_bib37","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s004240050358","article-title":"Cystic fibrosis and non-cystic-fibrosis human nasal epithelium show analogous Na+ absorption and reversible block by phenamil","volume":"434","author":"Blank","year":"1997","journal-title":"Pfl\u00fcgers Archiv"},{"key":"10.1016\/j.ejmech.2026.118968_bib38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1124\/jpet.107.130443","article-title":"Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)- N\u2032-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung","volume":"325","author":"Hirsh","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2026.118968_bib39","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1152\/jn.00012.2013","article-title":"Permeation and block of TRPV1 channels by the cationic lidocaine derivative QX-314","volume":"109","author":"Puopolo","year":"2013","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.ejmech.2026.118968_bib40","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1517\/13543776.2013.829454","article-title":"Novel small molecule epithelial sodium channel inhibitors as potential therapeutics in cystic fibrosis-A patent evaluation","volume":"23","author":"Schoenberger","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2026.118968_bib41","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jcf.2024.06.002","article-title":"ETD001: a novel inhaled ENaC blocker with an extended duration of action in vivo","volume":"24","author":"Danahay","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2026.118968_bib42","series-title":"Pyrazine Derivatives as ENaC Blockers","author":"Bhalay","year":"2012"},{"key":"10.1016\/j.ejmech.2026.118968_bib43","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.bmcl.2011.12.016","article-title":"Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 1: quaternary amines","volume":"22","author":"Hunt","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118968_bib44","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.bmcl.2012.02.067","article-title":"Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 2: \u03b1-Branched quaternary amines","volume":"22","author":"Hunt","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118968_bib45","series-title":"ENaC Blockers, WO 2011\/079087","author":"Laine","year":"2011"},{"key":"10.1016\/j.ejmech.2026.118968_bib46","series-title":"Novel 5-substituted Benzimidazolium Compounds","author":"Kley","year":"2015"},{"key":"10.1016\/j.ejmech.2026.118968_bib47","series-title":"SODIUM CHANNEL BLOCKERS, US 2010O144661A1","author":"Johnson","year":"2010"},{"key":"10.1016\/j.ejmech.2026.118968_bib48","first-page":"7","article-title":"Mucus clearance and lung function in cystic fibrosis with hypertonic saline","volume":"51","author":"Donaldson","year":"2007","journal-title":"Surv. Anesthesiol."},{"key":"10.1016\/j.ejmech.2026.118968_bib49","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.pupt.2013.07.009","article-title":"Airway drug pharmacokinetics via analysis of exhaled breath condensate","volume":"27","author":"Esther","year":"2014","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.118968_bib50","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1089\/jamp.2013.1037","article-title":"Acute hyperkalemia associated with inhalation of a potent ENaC antagonist: phase 1 trial of GS-9411","volume":"27","author":"O\u2019riordan","year":"2014","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ejmech.2026.118968_bib51","series-title":"3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTA-HYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL)CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE","author":"Johnson","year":"2020"},{"key":"10.1016\/j.ejmech.2026.118968_bib53","doi-asserted-by":"crossref","first-page":"L536","DOI":"10.1152\/ajplung.00454.2021","article-title":"Preclinical evaluation of the epithelial sodium channel inhibitor AZD5634 and implications on human translation","volume":"323","author":"\u00c5strand","year":"2022","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.ejmech.2026.118968_bib52","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S2213-2600(23)00226-6","article-title":"Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trial","volume":"12","author":"Ringshausen","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejmech.2026.118968_bib54","series-title":"Chemical Compounds, WO2015\/140527Al","author":"Berglund","year":"2015"},{"key":"10.1016\/j.ejmech.2026.118968_bib55","series-title":"Am J Med Crit Care Med [Int Conf Am Thorac Soc (May 19-24, Washington, D.C.)","first-page":"2017","article-title":"ENaC inhibitor AZD5634 augments airway surface liquid and mucociliary transport in primary cystic fibrosis airway cells","author":"Falk Libby","year":"2017"},{"key":"10.1016\/j.ejmech.2026.118968_bib56","series-title":"Am J Respir Crit Care Med [Int Conf Am Thorac Soc (May 18-23, San Diego) 2018]","article-title":"The ENaC inhibitor AZD5634 provides efficacious and resilient mucociliary clearance of sheep airways","author":"Astrand A","year":"2018"},{"key":"10.1016\/j.ejmech.2026.118968_bib57","series-title":"Am J Med Crit Care Med [Int Conf Am Thorac Soc (May 19-24, Washington, D.C.)","article-title":"Patel, ENaC inhibitor AZD5634 first in human trial reveals promising clinical profile for the treatment of cystic fibrosis","author":"Gardiner P","year":"2017"},{"key":"10.1016\/j.ejmech.2026.118968_bib58","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jcf.2022.02.010","article-title":"AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis","volume":"21","author":"Kristensson","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2026.118968_bib59","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0022-3565(25)39491-7","article-title":"Stereoselective blockade of amphibian epithelial sodium channels by amiloride analogs","volume":"267","author":"Li","year":"1993","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2026.118968_bib60","series-title":"ORGANIC COMPOUNDS, WO2008\/135557Al","author":"Fairhurst","year":"2008"},{"key":"10.1016\/j.ejmech.2026.118968_bib61","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1111\/bph.13075","article-title":"NVP-QBE170: an inhaled blocker of the epithelial sodium channel with a reduced potential to induce hyperkalaemia","volume":"172","author":"Coote","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118968_bib62","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1016\/j.bmcl.2015.07.015","article-title":"Discovery of highly potent, lung-localized epithelial sodium channel inhibitors","volume":"25","author":"Kumar","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.118968_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116038","article-title":"Discovery and development of BI 1265162, an ENaC inhibitor for the treatment of cystic fibrosis","volume":"265","author":"Betzemeier","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118968_bib64","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00429-2020","article-title":"Preclinical evaluation of the epithelial sodium channel inhibitor BI 1265162 for treatment of cystic fibrosis","volume":"6","author":"Nickolaus","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.ejmech.2026.118968_bib65","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00447-2020","article-title":"First clinical trials of the inhaled epithelial sodium channel inhibitor BI 1265162 in healthy volunteers","volume":"7","author":"Mackie","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.ejmech.2026.118968_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/13993003.00746-2021","article-title":"Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study","volume":"59","author":"Goss","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2026.118968_bib67","series-title":"Benzodiazolium Compounds as ENaC Inhibitors","author":"Mccarthy","year":"2018"},{"key":"10.1016\/j.ejmech.2026.118968_bib68","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/S1569-1993(22)00855-4","article-title":"164 Tolerance of ETD001, a long-acting inhaled epithelial sodium channel blocker, in humans","volume":"21","author":"Russell","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.ejmech.2026.118968_bib69","doi-asserted-by":"crossref","first-page":"L990","DOI":"10.1152\/ajplung.00103.2013","article-title":"Identification of the SPLUNC1 ENaC-inhibitory domain yields novel strategies to treat sodium hyperabsorption in cystic fibrosis airway epithelial cultures","volume":"305","author":"Hobbs","year":"2013","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.ejmech.2026.118968_bib70","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1164\/rccm.201612-2445OC","article-title":"SPX-101 is a novel epithelial sodium channel-targeted therapeutic for cystic fibrosis that restores mucus transport","volume":"196","author":"Scott","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2026.118968_bib71","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jcf.2018.06.002","article-title":"SPX-101 is stable in and retains function after exposure to cystic fibrosis sputum","volume":"18","author":"Sesma","year":"2019","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"10.1016\/j.ejmech.2026.118968_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2019.101819","article-title":"First clinical trials of novel ENaC targeting therapy, SPX-101, in healthy volunteers and adults with cystic fibrosis","volume":"58","author":"Couroux","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.118968_bib73","series-title":"TRYPTASE INHIBITOR AND NOVEL GUANIDINO DERIVATIVES","author":"Hiroshi","year":"1999"},{"key":"10.1016\/j.ejmech.2026.118968_bib74","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1164\/rccm.201511-2216OC","article-title":"Inhibition of protease-epithelial sodium channel signaling improves mucociliary function in cystic fibrosis airways","volume":"194","author":"Reihill","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2026.118968_bib75","article-title":"Novel inhibitors and activity-based probes targeting serine proteases","volume":"10","author":"Ferguson","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.ejmech.2026.118968_bib76","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.coph.2018.09.007","article-title":"The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis","volume":"43","author":"Shei","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118968_bib77","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1124\/jpet.108.148155","article-title":"Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease","volume":"329","author":"Coote","year":"2009","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2026.118968_bib78","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1378\/chest.12-2431","article-title":"Reduced sodium transport with nasal administration of the prostasin inhibitor camostat in subjects with cystic fibrosis","volume":"144","author":"Rowe","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.ejmech.2026.118968_bib79","author":"Douglas"},{"key":"10.1016\/j.ejmech.2026.118968_bib80","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1038\/mtna.2012.57","article-title":"Pharmacological characterization of a novel ENaC\u03b1 siRNA (GSK2225745) with potential for the treatment of cystic fibrosis","volume":"2","author":"Clark","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejmech.2026.118968_bib81","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jcf.2017.05.003","article-title":"Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice","volume":"16","author":"Crosby","year":"2017","journal-title":"J. Cyst. Fibros. Off. J. Eur. Cyst. Fibros. Soc."},{"key":"10.1016\/j.ejmech.2026.118968_bib82","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00986-2023","article-title":"Randomised, phase 1\/2a trial of ION-827359, an antisense oligonucleotide inhibitor of ENaC","volume":"10","author":"Sutharsan","year":"2024","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.ejmech.2026.118968_bib83","unstructured":"Arrowhead Pharmaceuticals presents preclinical data on ARO-ENaC at the North American Cystic Fibrosis Conference [news release]. Arrowhead Pharmaceuticals Inc. October 31, 2019. http:\/\/ir.arrowheadpharma.com\/email-alerts."},{"key":"10.1016\/j.ejmech.2026.118968_bib84","series-title":"Arrowhead Pharmaceuticals pauses ARO-ENaC Phase 1\/2 Clinical Study [news release]","year":"2021"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:37:49Z","timestamp":1783161469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426004137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":84,"alternative-id":["S0223523426004137"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118968","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A critical analysis on ENaC inhibitors, unravelling molecular medicinal insights and promising research roadmap in the treatment of cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118968","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118968"}}